OSI-930
- CAS NO.:728033-96-3
- Empirical Formula: C22H16F3N3O2S
- Molecular Weight: 443.44
- MDL number: MFCD11100358
- SAFETY DATA SHEET (SDS)
- Update Date: 2026-03-13 23:13:44
What is OSI-930?
The Uses of OSI-930
OSI-930 is an inhibitor of the receptor tyrosine kinases c-Kit (IC50:9.5nM) and VEGFR-2 (IC50:10.1nM).
What are the applications of Application
OSI-930 is a potent thiophene receptor tyrosine kinase inhibitor
Definition
ChEBI: 3-(4-quinolinylmethylamino)-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide is an aromatic amide.
Biological Activity
osi-930 is a novel, potent inhibitor of flt1, kinase insert domain receptor (kdr), csf-1r, lck, c-raf and activated receptor tyrosine kinases kit with ic50 values of 8, 9, 15, 22, 41 and 80 nm, respectively [1].osi-930 has been demonstrated to inhibit proliferation and induce apoptosis in the hmc-1 cell line which is highly dependent on kit signaling for survival. on the contrary, osi-930 revealed no growth inhibition of colo-205 cell line under normal culture conditions [1].osi-930 has shown to time- and concentration-dependently inactivate p450 3a4. additionally, osi-930 could reduce co difference spectra of p450 3a4 [2].
References
[1] garton aj1, crew ap, franklin m, cooke ar, wynne gm, castaldo l, kahler j, winski sl, franks a, brown en, bittner ma, keily jf, briner p, hidden c, srebernak mc, pirrit c, o'connor m, chan a, vulevic b,henninger d, hart k, sennello r, li ah, zhang t, richardson f, emerson dl, castelhano al, arnold ld,gibson nw. osi-930: a novel selective inhibitor of kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. cancer res. 2006 jan 15;66(2):1015-24.
[2] lin hl1, zhang h, medower c, hollenberg pf, johnson ww. inactivation of cytochrome p450 (p450) 3a4 but not p450 3a5 by osi-930, a thiophene-containing anticancer drug. drug metab dispos. 2011 feb;39(2):345-50.
Properties of OSI-930
| Boiling point: | 517.4±50.0 °C(Predicted) |
| Density | 1.450 |
| storage temp. | Store at -20°C |
| solubility | ≥22.15 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| form | solid |
| pka | 11.36±0.70(Predicted) |
| color | Light yellow to yellow |
Safety information for OSI-930
| Signal word | Warning |
| Pictogram(s) |
![]() Exclamation Mark Irritant GHS07 |
| GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for OSI-930
New Products
2-(2-aminoethyl) benzenesulfonamide Gemcitabine 3-benzoate impurity Dihydroxyphenylacetone Ornidazole EP impurity D Acetyl amino diol impurity Valsartan Benzyl Ester Impurity B N,N'-Dicyclohexylcarbodiimide 3-Bromo-2-Methyl-5-Nitropyridine 5-Bromo-3-Methyl-2-Pyridinecarboxylic acid 2-Amino-4-Methylpyridine 4-Aminopyridine 4-dimethylaminopyridineRelated products of tetrahydrofuran








You may like
-
4-(Methylnitrosoamino)-butanal NLT 95%View Details
339362-86-6 -
848696-99-1 NLT 95%View Details
848696-99-1 -
Ornidazole EP impurity A 1384752-15-1 NLT 95%View Details
1384752-15-1 -
615-81-6 Diisopropyl oxalate NLT 95%View Details
615-81-6 -
175481-38-6 Lacosamide EP Impurity F NLT 95%View Details
175481-38-6 -
S-Clopidogrel N-Methyl Impurity 1346605-15-9 NLT 95%View Details
1346605-15-9 -
Valsartan Related Compound A NLT 95%View Details
137862-87-4 -
Losartan Propyl BCFI 124750-49-8 NLT 95%View Details
124750-49-8

